Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
This report contains market size and forecasts of Adrenoleukodystrophy Treatment in Global, including the following market information:
Global Adrenoleukodystrophy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Adrenoleukodystrophy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Adrenoleukodystrophy Treatment include bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenoleukodystrophy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Type, 2021 (%)
Oral Drugs
Parenteral Drugs
Global Adrenoleukodystrophy Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Home Care
Global Adrenoleukodystrophy Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Adrenoleukodystrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adrenoleukodystrophy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Adrenoleukodystrophy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
bluebird bio
Orpheris
MedDay Pharmaceuticals
MINORYX THERAPEUTICS SL
Pfizer
Amgen
AstraZeneca
Abbott
agtc
ReceptoPharm
The Myelin Project
SOM Biotech
Viking Therapeutics
Nutra Pharma Corporation
Genetix Biotech
Magenta Therapeutics
NeuroVia
Novartis
CELGENE CORPORATION
Jazz Pharmaceuticals
Sanofi